| 2024-05-16 |
JAMA Oncology Peer Reviewers in 2023 |
|
|
| 2024-05-16 |
Hypofractionated vs Conventional Postprostatectomy Radiotherapy for GI and GU Symptoms |
|
|
| 2024-05-16 |
Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma |
|
|
| 2024-05-16 |
Hypofractionation for Postprostatectomy Radiotherapy |
|
|
| 2024-05-16 |
PARP Inhibitors for Breast Cancer Treatment |
|
|
| 2024-05-16 |
Neoadjuvant Chemoimmunotherapy for NSCLC |
|
|
| 2024-05-16 |
The SOUND Randomized Clinical Trial Results |
|
|
| 2024-05-16 |
Error in Byline |
|
|
| 2024-05-16 |
Comment on the Burden of Infection-Attributable Cancers in the US |
|
|
| 2024-05-16 |
The Potential of Wearable Devices in Cancer Care Delivery |
|
|
| 2024-05-16 |
Physical Activity as an Alternative to Performance Status in Patients With Advanced Lung Cancer |
|
|
| 2024-05-16 |
Machine Learning–Based Prediction of Hospitalization During Chemoradiotherapy With Daily Step Counts |
|
|
| 2024-05-16 |
Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies |
|
|
| 2024-05-16 |
Error in Author Degree |
|
|
| 2024-05-16 |
JAMA Oncology |
|
|
| 2024-05-16 |
Prospective Data on Stereotactic Ablative Radiotherapy Provides Guidance in an Unusual Scenario |
|
|
| 2024-05-16 |
Relugolix Plus Radiotherapy in Localized or Advanced Prostate Cancer |
|
|
| 2024-05-16 |
Comment on the Burden of Infection-Attributable Cancers in the US |
|
|
| 2024-05-16 |
The SOUND Randomized Clinical Trial Results |
|
|
| 2024-05-16 |
Comment on the Burden of Infection-Attributable Cancers in the US—Reply |
|
|
| 2024-05-16 |
The SOUND Randomized Clinical Trial Results—Reply |
|
|
| 2024-05-16 |
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2 -Positive Breast Cancer |
|
|
| 2024-05-16 |
Nonverbal |
|
|
| 2024-05-16 |
Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma |
|
|
| 2024-05-16 |
The Ethics of Hope—A Moral Imperative for Oncologists |
|
|
| 2024-05-16 |
Cancer Care in the Era of AI |
|
|
| 2024-05-16 |
Patterns of Undertreatment and Overtreatment for Early-Stage Endometrial Cancer |
|
|
| 2024-05-16 |
Dog Aloisanov Helped Diagnose My Cancer |
|
|
| 2024-05-16 |
Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma—Reply |
|
|
| 2024-05-16 |
Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time |
|
|
| 2024-05-16 |
Unveiling the Untapped Potential of Antibody Drug Conjugates in Precision Oncology |
|
|
| 2024-05-16 |
The Chemoimmunotherapy Revolution in Resectable Non-Small Cell Lung Cancer |
|
|
| 2024-05-16 |
Precision Irradiation in Early Non–Small Cell Lung Cancer and Interstitial Lung Disease |
|
|
| 2024-05-16 |
JAMA Oncology —The Year in Review, 2023 |
|
|
| 2024-05-16 |
Charting the Path to Systemic Therapy De-escalation |
|
|
| 2024-05-16 |
The SOUND Randomized Clinical Trial Results |
|
|
| 2024-04-18 |
Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma |
|
|
| 2024-04-18 |
Broken Promises |
|
|
| 2024-04-18 |
TMB in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition |
|
|
| 2024-04-18 |
Pertuzumab Plus Trastuzumab Without Chemotherapy for ERBB2-Positive Metastatic Breast Cancer—Reply |
|
|
| 2024-04-18 |
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma |
|
|
| 2024-04-18 |
Modernize Precision Oncology With Decentralized Trial Tools |
|
|
| 2024-04-18 |
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations |
|
|
| 2024-04-18 |
Errors in Author Affiliations and Figure 2 |
|
|
| 2024-04-18 |
PFS Analysis With a Graphical Estimand Approach in the Phase 2 SAMCO-PRODIGE 54 Trial |
|
|
| 2024-04-18 |
PFS Analysis With a Graphical Estimand Approach in the Phase 2 SAMCO-PRODIGE 54 Trial—Reply |
|
|
| 2024-04-18 |
Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations |
|
|
| 2024-04-18 |
Error in Text |
|
|
| 2024-04-18 |
Errors in Author Contributions, Methods, and Figures 1 and 2 |
|
|
| 2024-04-18 |
Association of Skin Microbiome Dynamics With Radiodermatitis in Patients With Breast Cancer |
|
|
| 2024-04-18 |
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations |
|
|
| 2024-04-18 |
Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma—Reply |
|
|
| 2024-04-18 |
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer |
|
|
| 2024-04-18 |
Error in Text |
|
|
| 2024-04-18 |
Advancing Truth in Oncology by Complementing Clinical Trials With Evidence From Clinical Practice |
|
|
| 2024-04-18 |
Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access |
|
|
| 2024-04-18 |
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer |
|
|
| 2024-04-18 |
Hyperbaric Oxygen Therapy for Management of Late Radiation Toxicity |
|
|
| 2024-04-18 |
Error in Affiliations |
|
|
| 2024-04-18 |
Pertuzumab Plus Trastuzumab Without Chemotherapy for ERBB2-Positive Metastatic Breast Cancer |
|
|
| 2024-04-18 |
Features and Factors Associated With Myeloid Neoplasms After CART |
|
|
| 2024-04-18 |
MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases |
|
|
| 2024-04-18 |
Undiagnosed US Cancer Cases During the COVID-19 Pandemic |
|
|
| 2024-04-18 |
Hyperbaric Oxygen Therapy and Late Local Toxic Effects in Patients With Irradiated Breast Cancer |
|
|
| 2024-04-18 |
Accreditation Standards for Cancer Equity |
|
|
| 2024-04-18 |
The Threat of Florida’s New Legislation on Undocumented Individuals |
|
|
| 2024-04-18 |
Response to 2 Induction Courses of BCG Therapy Among Patients With High-Risk NMIBC |
|
|
| 2024-04-18 |
Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma |
|
|
| 2024-04-18 |
Considerations for Prompting Large Language Models |
|
|
| 2024-04-18 |
Federal Transportation Regulations Limit Access to Clinical Trials and Oncology Care |
|
|
| 2024-04-18 |
Considerations for Prompting Large Language Models—Reply |
|
|
| 2024-04-18 |
Error in Visual Abstract |
|
|
| 2024-04-18 |
JAMA Oncology |
|
|
| 2021-03-23 |
Trends in Industry Payments to US Oncologists Since the Open Payments Program, 2014 to 2019 |
Tarras ES, Marshall DC, Rosenzweig K, et al. |
|
| 2021-03-23 |
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Triple-Negative Breast Cancer—Reply |
Yu K, Shao Z. |
|
| 2021-03-23 |
When the Signal From Phase 2 Research Should Be a Warning Sign |
West H. |
|
| 2021-03-23 |
Incidence of Cervical Cancer in Puerto Rico, 2001-2017 |
Ortiz A, Ortiz-Ortiz KJ, Colón-López V, et al. |
|
| 2021-03-23 |
Nonmedical Opioid Use Behavior Among Patients With Cancer Receiving Opioids for Cancer Pain |
Yennurajalingam S, Arthur J, Reddy S, et al. |
|
| 2021-03-23 |
Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography |
Eldred-Evans D, Burak P, Connor MJ, et al. |
|
| 2021-03-23 |
Radiation Delay Is Okay, but Where Is the Evidence? |
Mohamad O, Roach M, III. |
|
| 2021-03-23 |
Error in Coauthor’s Affiliation |
|
|
| 2021-03-23 |
Aspirin Use and Risk of Colorectal Cancer Among Older Adults |
Guo C, Ma W, Drew DA, et al. |
|
| 2021-03-23 |
Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma |
Baa A, Rastogi S. |
|
| 2021-03-23 |
Aligning Cancer Clinical Trials With Cancer Burden |
Desai A, Kuderer NM, Lyman GH. |
|
| 2021-03-23 |
Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma—Reply |
Wagner MJ, Cranmer LD, Pollack SM. |
|
| 2021-03-23 |
An Analysis of Contemporary Oncology Randomized Clinical Trials |
Wells J, Sharma S, Del Paggio JC, et al. |
|
| 2021-03-23 |
Community-Based Screening for Prostate Cancer |
Lee SI, O’Shea A. |
|
| 2021-03-23 |
Treatment Deescalation Strategies for Nasopharyngeal Cancer |
Lee A, Chow JH, Lee NY. |
|
| 2021-03-23 |
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma |
Sohal DS, Duong M, Ahmad SA, et al. |
|
| 2021-03-23 |
Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer |
Ramaswamy A, Ostwal V, Sharma A, et al. |
|
| 2021-03-23 |
Race/Ethnicity and the 21-Gene Recurrence Score and Breast Cancer–Specific Mortality Among US Women |
Hoskins KF, Danciu OC, Ko NY, et al. |
|
| 2021-03-23 |
Radiation Delay Is Okay, but Where Is the Evidence?—Reply |
Dee E, D’Amico AV, Muralidhar V. |
|
| 2021-03-23 |
Natural Language Processing to Assess Documentation for Patients With Colorectal Cancer—Reply |
Agaronnik ND, Lindvall C, Iezzoni LI. |
|
| 2021-03-23 |
Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic |
Bakouny Z, Paciotti M, Schmidt AL, et al. |
|
| 2021-03-23 |
Natural Language Processing to Assess Documentation for Patients With Colorectal Cancer |
Sun L. |
|
| 2021-03-23 |
Sequential Chemotherapy for Early-Stage, Post–Radical Hysterectomy Cervical Cancer |
Randall LM, Mayadev J, Monk BJ. |
|
| 2021-03-23 |
Natural Language Processing to Assess Documentation for Patients With Colorectal Cancer |
Ooi R, Ooi S. |
|
| 2021-03-23 |
Osimertinib Plus Bevacizumab vs Osimertinib in Advanced Lung Cancer Previously Treated With EGFR-TKI |
Akamatsu H, Toi Y, Hayashi H, et al. |
|
| 2021-03-23 |
Deconstructing Racial and Ethnic Disparities in Breast Cancer |
Sparano JA, Brawley OW. |
|
| 2021-03-23 |
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Triple-Negative Breast Cancer |
Arora S, Kumar A, Batra A. |
|
